308 related articles for article (PubMed ID: 30385408)
21. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
22. Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
Ruan H; Bao L; Tao Z; Chen K
Cancer Immunol Res; 2021 Jul; 9(7):838-852. PubMed ID: 34011528
[TBL] [Abstract][Full Text] [Related]
23. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
24. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830179
[TBL] [Abstract][Full Text] [Related]
25. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
26. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
27. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
Baas W; Gershburg S; Dynda D; Delfino K; Robinson K; Nie D; Yearley JH; Alanee S
Clin Genitourin Cancer; 2017 Oct; 15(5):577-581. PubMed ID: 28461179
[TBL] [Abstract][Full Text] [Related]
28. [Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
Kataoka K
Gan To Kagaku Ryoho; 2017 Nov; 44(11):967-971. PubMed ID: 29138368
[TBL] [Abstract][Full Text] [Related]
29. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
[TBL] [Abstract][Full Text] [Related]
30. ERα is a negative regulator of PD-L1 gene transcription in breast cancer.
Liu L; Shen Y; Zhu X; Lv R; Li S; Zhang Z; Shi YG; Tan L
Biochem Biophys Res Commun; 2018 Oct; 505(1):157-161. PubMed ID: 30241942
[TBL] [Abstract][Full Text] [Related]
31. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
32. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.
Zhang Y; Zhu S; Du Y; Xu F; Sun W; Xu Z; Wang X; Qian P; Zhang Q; Feng J; Xu Y
J Exp Clin Cancer Res; 2022 Feb; 41(1):66. PubMed ID: 35177112
[TBL] [Abstract][Full Text] [Related]
33. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.
Dorighi KM; Swigut T; Henriques T; Bhanu NV; Scruggs BS; Nady N; Still CD; Garcia BA; Adelman K; Wysocka J
Mol Cell; 2017 May; 66(4):568-576.e4. PubMed ID: 28483418
[TBL] [Abstract][Full Text] [Related]
34. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Wang YF; Liu F; Sherwin S; Farrelly M; Yan XG; Croft A; Liu T; Jin L; Zhang XD; Jiang CC
J Invest Dermatol; 2018 Apr; 138(4):922-932. PubMed ID: 29174371
[TBL] [Abstract][Full Text] [Related]
35. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion.
Du L; Lee JH; Jiang H; Wang C; Wang S; Zheng Z; Shao F; Xu D; Xia Y; Li J; Zheng Y; Qian X; Li X; Kim HR; Xing D; Liu P; Lu Z; Lyu J
J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32860047
[TBL] [Abstract][Full Text] [Related]
36. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
[TBL] [Abstract][Full Text] [Related]
37. Autophagy inhibition enhances PD-L1 expression in gastric cancer.
Wang X; Wu WKK; Gao J; Li Z; Dong B; Lin X; Li Y; Li Y; Gong J; Qi C; Peng Z; Yu J; Shen L
J Exp Clin Cancer Res; 2019 Mar; 38(1):140. PubMed ID: 30925913
[TBL] [Abstract][Full Text] [Related]
38. MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity.
Zheng JY; Wang CY; Gao C; Xiao Q; Huang CW; Wu M; Li LY
Cell Death Dis; 2021 Apr; 12(4):364. PubMed ID: 33824309
[TBL] [Abstract][Full Text] [Related]
39. MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC; Tong L; Li Y; Do R; Walz S; Fitzgerald KN; Gouw AM; Baylot V; Gütgemann I; Eilers M; Felsher DW
Science; 2016 Apr; 352(6282):227-31. PubMed ID: 26966191
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
Micevic G; Thakral D; McGeary M; Bosenberg MW
Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]